Navigation Links
NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
Date:2/5/2013

Madison, WI (PRWEB) February 05, 2013

The Promega PowerPlex® Y23 System is now approved for use in laboratories that generate DNA records for the National DNA Index System (NDIS). NDIS is the US national database containing over ten million offender profiles used to help authorities in solving criminal investigations nationwide.

Launched in July 2012, the PowerPlex Y23 System is a rapid human identification Y-chromosome short tandem repeat (Y-STR) assay for forensic casework, offender databasing and relationship testing. Thermal cycling time is cut roughly in half, and the system detects substantially more Y-STR loci than current systems. The multiplex system co-amplifies 23 Y-STR loci, providing maximum discrimination. In addition, these 23 loci include all of the Y-STR loci found in key public STR databases in the US and Europe.

The system works with extracted DNA, including DNA from difficult samples with lower amounts of template and male:female mixtures. Streamlined protocols are provided for all sample types. The combination of reduced sample preparation time and shorter cycling times results in a significant reduction in total time to process samples. For many laboratories, this will save more than a half day per plate.

The additional loci and increased haplotype resolution improve scientists’ ability to distinguish individuals from different paternal lines. The PowerPlex Y23 System is useful in multiple applications, including paternity testing, offender databasing and forensic casework such as sexual assault cases, missing persons investigations and familial searching initiatives.

PowerPlex is a registered trademark of Promega Corporation.

Promega Corporation has provided products for DNA-based human identification for over 20 years. Promega is a leader in providi
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
2. Watsons Generic Yaz(R) Receives FDA Approval
3. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
4. FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Watsons Generic BONIVA® 150mg Receives FDA Approval
7. Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
8. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
9. FDA Issues Orphan Status Approval for PermaDerm®
10. West Wireless Health Institute Applauds House Passage of Bill to Streamline FDA Medical Device Approval Process, Expedite Mobile Medical App Guidance
11. Lupin Receives FDA Approval for Generic LYRICA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ( ... cell biotechnologies. Currently the company holds seven recently ... applications currently under examination by the U.S. Patent and ... the most vexing problems in adult stem cell biology ... difficult to identify; and they have been difficult to ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... A ... Biology are Natural Partners in the Fight Against Disorder. , ... (PRWEB) November 3, 2009 -- MyPhield Technology ... naturally relieves osteoarthritis without causing unwanted side-effects, is now available online at www.ReliefForLife.ca ...
... 3 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... 30, 2009. ISTA reported net revenue of $32.0 million ... increase over net revenue for the three months ended September ... months ended September 30, 2009 is $1.2 million associated with ...
... SAN MARCOS, Texas, Nov. 3 Texas State University ... agreement today that will permit University Researchers to continue ... potential and effectiveness of ALKA-V6, a compound which has ... the HIV virus in laboratory experiments. , The research ...
Cached Biology Technology:New Technology Now Available In Canada For Osteoarthritis 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 2Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound 3
(Date:7/31/2014)... brown and beige adipocytes, or fat cells, are inherently ... and each plays its own role in metabolism. In ... the most prevalent. Its primary function is energy storage. ... to generate heat but are only found in a ... which represent a special type of brown adipocytes, appear ...
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... change on the world,s animal and plant species ... a new paper by a research team from ... other organizations. The authors claim that most of ... it comes to climate change. , While ... the "direct" threats of changing temperatures and precipitation ...
Breaking Biology News(10 mins):Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... 23 GenVault Corporation, the leader in ambient temperature ... announced that David Wellis, Ph.D., GenVault,s President and CEO, ... place on October 26th and 27th in La Jolla, ... an overview of the company together with recent customer, ...
... HILL Scientists at the University of North Carolina ... of California, San Francisco have developed and experimentally tested ... drugs. The researchers developed a computational method that ... are to the naturally occurring binding partners -- known ...
... MADISON, WI, NOVEMBER 4, 2009 -- The world,s greatest wines ... input, and something called the "terroir" -- a term often defined ... will discuss terroir with an emphasis on soil science in a ... the Environment" will be presented in two parts at the 2009 ...
Cached Biology News:GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2Great wines come from great soils 2